# reload+after+2024-01-21 11:43:34.373550
address1§Denver Corporate Center III
address2§7900 East Union Avenue Suite 920
city§Denver
state§CO
zip§80237
country§United States
phone§720 437 6580
website§https://aytubio.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.
fullTimeEmployees§150
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Joshua R. Disbrow', 'age': 48, 'title': 'Chairman & CEO', 'yearBorn': 1975, 'fiscalYear': 2023, 'totalPay': 708000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark K. Oki CPA', 'age': 54, 'title': 'CFO, Secretary & Treasurer', 'yearBorn': 1969, 'fiscalYear': 2023, 'totalPay': 522840, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Greg  Pyszczymuka', 'age': 44, 'title': 'Chief Commercial Officer', 'yearBorn': 1979, 'fiscalYear': 2023, 'totalPay': 525000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Victoria  Cordova', 'title': 'Vice President of People & Culture', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jarrett T. Disbrow Ph.D.', 'age': 48, 'title': 'Chief Business Officer & President of Consumer Health', 'yearBorn': 1975, 'fiscalYear': 2023, 'totalPay': 355000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Russ  McMahen', 'title': 'Senior Vice President of Research & Development', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ryan J. Selhorn CPA', 'age': 41, 'title': 'Executive VP of Finance & Business Optimization', 'yearBorn': 1982, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.995
priceToSalesTrailing12Months§0.14924195
currency§USD
dateShortInterest§1702598400
forwardEps§0.62
exchange§NCM
quoteType§EQUITY
shortName§Aytu BioPharma, Inc.
longName§Aytu BioPharma, Inc.
firstTradeDateEpochUtc§1222349400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§887c97be-184b-3c68-ac18-63df37b78e4c
gmtOffSetMilliseconds§-18000000
targetHighPrice§5.0
targetLowPrice§5.0
targetMeanPrice§5.0
targetMedianPrice§5.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§0.761
grossMargins§0.62237
ebitdaMargins§-0.03374
trailingPegRatio§None
